Redeye: Xbrane Biopharma Q4 2022 - Just ahead of launch

2023-02-21 11:32:00

Redeye slightly adjusts its fair value range of Xbrane on the back of the Q4 report. Considering the significant valuation discount compared to peer biosimilar developers and a year containing high-impact catalysts, we see good prospects for an upside opportunity.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.